Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404885 · ClinicalTrials.gov registry record · Phase 3
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
A Phase 3 study of Uveitis, Anterior and Panuveitis, sponsored by Lux Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT00404885 is a Phase 3 study of Uveitis, Anterior and Panuveitis that has completed, run by Lux Biosciences. The registered enrollment target is 108 participants, above the 61-participant average among 4 other Uveitis, Anterior trials with a reported enrollment target (77% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT00404885, a Phase 3 study of Uveitis, Anterior and Panuveitis, has completed, sponsored by Lux Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LX211
Study Locations (20)
Other
- Universitätsklinik für Augenheilkunde - Salzburg
- Klinik für Augenheilkunde, Dept. of Ophthalmology - Vienna
- Hôpital Pitié Salpétrière, Service d'Ophtalmologie - Paris
- Universitätsklinikum Freiburg - Freiburg im Breisgau
- Augenklinik der Universität Heidelberg - Heidelberg
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
- Massachusetts Eye Research and Surgery Institute - Cambridge
Texas
- Brian B. Berger, MD, P.A. - Austin
- Retina & Uveitis Consultants of Texas - San Antonio
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Retinal Consultants of Arizona - Phoenix
Illinois
- University of Illinois - Chicago - Chicago
Maryland
- Wilmer Eye Institute - Baltimore
Michigan
- Associated Retinal Consultants, PC - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404885
The ClinicalTrials.gov registry entry for NCT00404885 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 61-participant average among 4 other Uveitis, Anterior trials with a reported enrollment target (77% higher). The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uveitis, Anterior appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00404885 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT00404885 about?
NCT00404885 is a clinical study titled "A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis". The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
What is the current status of trial NCT00404885?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2007-01. Estimated completion is 2009-05.
What conditions does trial NCT00404885 study?
This clinical trial studies the following conditions: Uveitis, Anterior, Panuveitis.
What interventions are being tested in trial NCT00404885?
The interventions under investigation include: Placebo (DRUG), LX211 (DRUG).
Who is sponsoring clinical trial NCT00404885?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00404885 being conducted?
This trial has 20 study locations across Alabama, Arizona, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis, Anterior
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
COMPLETED · Phase 3
-
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
COMPLETED
-
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.